Advertisement
U.S. markets open in 9 hours 1 minute
  • S&P Futures

    5,210.50
    -4.25 (-0.08%)
     
  • Dow Futures

    39,220.00
    -3.00 (-0.01%)
     
  • Nasdaq Futures

    18,190.75
    -40.75 (-0.22%)
     
  • Russell 2000 Futures

    2,049.70
    -0.10 (-0.00%)
     
  • Crude Oil

    82.72
    0.00 (0.00%)
     
  • Gold

    2,164.90
    +0.60 (+0.03%)
     
  • Silver

    25.34
    +0.08 (+0.32%)
     
  • EUR/USD

    1.0875
    -0.0001 (-0.01%)
     
  • 10-Yr Bond

    4.3400
    -4.3400 (-100.00%)
     
  • Vix

    14.33
    -0.08 (-0.56%)
     
  • GBP/USD

    1.2720
    -0.0009 (-0.07%)
     
  • USD/JPY

    149.8310
    +0.7330 (+0.49%)
     
  • Bitcoin USD

    65,584.37
    -2,410.95 (-3.55%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,722.55
    -4.87 (-0.06%)
     
  • Nikkei 225

    39,755.87
    +15.47 (+0.04%)
     

Drugmaker Valeant reports better-than-expected profit

Oct 20 (Reuters) - Canada's Valeant Pharmaceuticals International Inc , embroiled in a bitter fight to take over Botox-maker Allergan Inc, posted a better-than-expected quarterly profit, helped by strong sales in all its markets.

Valeant posted a profit attributable to the company of $275.4 million, or 81 cents per share, in the third quarter ended Sept. 30, compared with a loss of $973.2 million, or $2.92 cents per share, a year earlier.

In the year-earlier quarter, the company took a restructuring charge of $305 million, primarily related to the acquisition of Bausch & Lomb, and an impairment charge of $645 million.

Cash earnings, or profit adjusted for one-time items, was $2.11 per share, above the average analyst estimate of $1.99 per share, according to Thomson Reuters I/B/E/S.

(Reporting by Rod Nickel in Winnipeg, Manitoba and Ashutosh Pandey in Bangalore; Editing by Saumyadeb Chakrabarty)

Advertisement